The ATOS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ATOS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ATOS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View ATOS Detailed Price Forecast - CNN Money | View ATOS Detailed Summary - Google Finance | ||
View ATOS Detailed Summary - Yahoo! Finance | View ATOS Stock Research & Analysis - Zacks.com |
View ATOS Trends & Analysis - Trade-Ideas | View ATOS Major Holders - Barrons | ||
View ATOS Call Transcripts - NASDAQ | View ATOS Breaking News & Analysis - Seeking Alpha | ||
View ATOS Annual Report - CompanySpotlight.com | View ATOS OTC Short Report - OTCShortReport.com | ||
View ATOS Fundamentals - TradeKing | View ATOS SEC Filings - Bar Chart | ||
View Historical Prices for ATOS - The WSJ | View Performance/Total Return for ATOS - Morningstar | ||
View the Analyst Estimates for ATOS - MarketWatch | View the Earnings History for ATOS - CNBC | ||
View the ATOS Earnings - StockMarketWatch | View ATOS Buy or Sell Recommendations - MacroAxis | ||
View the ATOS Bullish Patterns - American Bulls | View ATOS Short Pain Metrics - ShortPainBot.com |
View ATOS Stock Mentions - StockTwits | View ATOS Stock Mentions - PennyStockTweets | ||
View ATOS Stock Mentions - Twitter | View ATOS Investment Forum News - Investor Hub | ||
View ATOS Stock Mentions - Yahoo! Message Board | View ATOS Stock Mentions - Seeking Alpha |
View Insider Transactions for ATOS - SECform4.com | View Insider Transactions for ATOS - Insider Cow | ||
View ATOS Major Holdings Summary - CNBC | View Insider Disclosure for ATOS - OTC Markets | ||
View Insider Transactions for ATOS - Yahoo! Finance | View Institutional Holdings for ATOS - NASDAQ |
View ATOS Stock Insight & Charts - FinViz.com | View ATOS Investment Charts - StockCharts.com | ||
View ATOS Stock Overview & Charts - BarChart | View ATOS User Generated Charts - Trading View |
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Posted on Monday April 15, 2024
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines i
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Posted on Thursday April 11, 2024
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET. The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference. Atossa is a clinical st
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Posted on Tuesday April 09, 2024
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer. Atossa is a cli
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Posted on Monday April 01, 2024
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study scheduled to be presented at 2024 AACR Annual MeetingEnded 2023 with $88.5 million of cash and cash equivalents and no debt SEATTLE, April 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced financial results for the fourth quarter and ful